For research use only. Not for therapeutic Use.
BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research[1].
| Catalog Number | I041725 |
| CAS Number | 688050-42-2 |
| Synonyms | N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(4-fluorophenyl)-1,2-oxazole-3-carboxamide |
| Molecular Formula | C19H16FN3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H16FN3O3S/c20-11-7-5-10(6-8-11)14-9-13(23-26-14)18(25)22-19-16(17(21)24)12-3-1-2-4-15(12)27-19/h5-9H,1-4H2,(H2,21,24)(H,22,25) |
| InChIKey | ROZYTPXUZIIHHA-UHFFFAOYSA-N |
| SMILES | C1CCC2=C(C1)C(=C(S2)NC(=O)C3=NOC(=C3)C4=CC=C(C=C4)F)C(=O)N |
| Reference | [1]. Cao R, et al. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules. J Chem Inf Model. 2015 Nov 23;55(11):2435-42. |
